A5028855621- Sarcoma Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Head and Neck Cancer Studies
- Colorectal and Anal Carcinomas
- Cancer Diagnosis and Treatment
- Radiation Dose and Imaging
- Cancer survivorship and care
- Bone Tumor Diagnosis and Treatments
- Trauma Management and Diagnosis
- Lung Cancer Treatments and Mutations
- Traumatic Brain Injury Research
- Soft tissue tumors and treatment
- Streptococcal Infections and Treatments
- Gastrointestinal Tumor Research and Treatment
- Management of metastatic bone disease
- Childhood Cancer Survivors' Quality of Life
- Cardiac tumors and thrombi
- Cancer Genomics and Diagnostics
- Advanced Radiotherapy Techniques
- Lung Cancer Diagnosis and Treatment
- Telemedicine and Telehealth Implementation
- Brain Metastases and Treatment
- Magnesium in Health and Disease
- Tracheal and airway disorders
- Cancer-related gene regulation
Beatson West of Scotland Cancer Centre
2018-2025
University of Kentucky HealthCare
2024-2025
University of Strathclyde
2021-2024
University of South Carolina
2023
Glasgow Royal Infirmary
2023
University of Kentucky
2023
Takeda (United States)
2021
Adaptimmune (United Kingdom)
2021
Baxter (United States)
2021
Janssen (Switzerland)
2021
BackgroundThe incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity standard cisplatin treatment, but no randomised evidence exists efficacy strategy.MethodsWe did open-label controlled phase 3 trial at 32 head and neck centres Ireland, Netherlands, UK, patients aged 18...
Mutations in the HRAS (mHRAS) proto-oncogene occur 4%-8% of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Tipifarnib is a farnesyltransferase inhibitor that disrupts function. We evaluated efficacy tipifarnib R/M mHRAS HNSCC.We enrolled 30 HNSCC single-arm, open-label phase II trial for malignancies; one additional patient was treated on an expanded access program. After ad hoc analysis first 16 variant allele frequency (VAF) data, enrollment...
Background: Necrotizing skin and soft tissue infections (NSTIs) are life threatening, requiring antibiotic agents surgical intervention. Clindamycin or linezolid is recommended as an adjunct therapy for toxin mediation; however, limited data comparing clindamycin-based to linezolid-based regimens in NSTI. Methods: This single-center retrospective study included adults with NSTI admitted the intensive care unit (ICU) at University of Kentucky HealthCare debridement between January 2017 June...
Introduction/Objective: Significant advancements have been achieved with the use of targeted molecular therapies for treatment Soft Tissue Sarcomas (STS). However, data remains scarce about potential benefits and toxicity this therapeutic option. In narrative review, we aim to better clarify wound healing complications in STS patients undergoing neoadjuvant (NA) radiotherapy (RT), combined therapies. Methods: We used PubMed database retrieve journal articles inclusion criteria were all...
Sarcomas comprise 1% of adult tumors and are very heterogeneous. Long-lasting cumulative treatment side-effects detract from the (progression-free) survival benefit treatment. Therefore, it is important to assess effectiveness in terms patient-reported outcomes (PROs), including health-related quality life (HRQoL) as well. However, questionnaires capturing unique issues sarcoma patients currently lacking. Given heterogeneity disease, development such an instrument may be challenging. The...
The study aimed to assess the suitability of deformable image registration (DIR) software generate synthetic CT (sCT) scans for dose verification during radiotherapy head and neck. Planning volume histograms were compared evaluate dosimetric changes treatment course.
Decision-making in the management of patients with retroperitoneal sarcoma is complex and requires input from a number different specialists. The aim this study was to evaluate levels agreement terms resectability, treatment allocation, organs proposed be resected across multidisciplinary team meetings.The CT scans clinical information 21 anonymized were sent all meetings Great Britain, which asked give an opinion about resected. main outcome inter-centre reliability, quantified using...
In Scotland, approximately 350 sarcoma cases are diagnosed per year and treated in one of the five specialist centers. Many patients required to travel long distances access care. The COVID-19 pandemic brought a number rapid changes into care for with cancer, increasing utilization telemedicine. We aimed evaluate how telemedicine affects professionals across Scotland delivery, at Beatson West Cancer Centre Sarcoma Unit.Between June 8 August 25, 2020, we invited professional multidisciplinary...
Imatinib is a specific tyrosine kinase inhibitor which has been approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia and c-KIT (CD117)-positive gastrointestinal stromal tumours. It associated with hepatotoxicity ranging from abnormal liver function tests to acute failure along hepatitis B reactivation. We report case patient who was started on adjuvant imatinib following resection primary cell tumour jejunum developed severe hepatotoxicity. There no...
Cutaneous sarcomas comprise a broad group of rare, heterogeneous mesenchymal tumours. The present report describes single centre experience regarding the management and outcomes patients with superficial soft tissue (SSTS). Key prognostic factors in predicting overall survival (OS) local relapse‑free were determined. Data from 66 SSTS treated surgically within Edinburgh Lothian collected context service evaluation. Patient demographics, tumour specifics treatment, as well 5‑year OS...
Abstract Background: This Phase 2 study (NCT02383927) is a multi-institutional, open-label trial to determine the efficacy and safety of tipifarnib in patients (pts) with locally advanced/unresectable and/or metastatic solid tumors that carry HRAS missense mutations. proto-oncogene overexpressed mutated head neck squamous cell carcinomas (HNSCC) other SCCs. Tipifarnib potent highly selective inhibitor farnesyltransferase, critical enzyme for activity. Methods: Pts received at starting dose...
Thoracic and breast sarcomas constitute a rare subgroup within the sarcoma population. There is limited knowledge about their health-related quality of life (HRQoL) valid disease-specific HRQoL instrument lacking. This qualitative study aimed to investigate issues experienced by small group thoracic patients. Semi-structured interviews with 19 four patients were conducted thematically analysed. Physical mentioned both groups fatigue, sleep disturbances, pain, wound infections, symptoms...
This case reports the synchronous diagnosis of two rare unrelated diseases; leiomyosarcoma and tenosynovial giant cell tumor knee. It focuses on challenges diagnosing tumor, including cognitive biases in clinical medicine that delay diagnosis. also demonstrates pathogenic etiology evidenced by transient deterioration patients' knee symptoms following administration prophylactic granulocyte colony-stimulating factor given as part chemotherapeutic regime for leiomyosarcoma.A 37-year-old...
Paraneoplastic neurological disorders are uncommon presentations of head and neck cancers. We present a case 68-year-old male patient who presented with dizziness, nausea memory problems. MRI his brain showed bilateral cerebellar leptomeningeal enhancing signal abnormality cervical lymphadenopathy. CT imaging raised the suspicion tonsillar primary, which was later confirmed on biopsy. His poorly differentiated HPV positive squamous cell carcinoma treated chemoradiotherapy. Subsequent...